According to Recursive Capital’s strategy, the fund targets early-stage companies, providing equity investments ranging from $50,000 to $100,000 per portfolio company.
In addition to enhancing operational efficiencies, PBR’s platform promotes inclusivity in clinical trials by ensuring underrepresented patient populations are considered.
In addition to enhancing operational efficiencies, PBR’s platform promotes inclusivity in clinical trials by ensuring underrepresented patient populations are considered.
